The Hepatitis C Virus Antibody ELISA Test Kit Market is seeing steady development as healthcare systems place greater focus on early detection and monitoring of hepatitis C. According to WiseGuyReports, the market is expected to grow from USD 1.087 billion in 2025 to USD 1.5 billion by 2035 at a 3.2% CAGR.

Manufacturers are investing in automated testing platforms that can improve accuracy, consistency, and laboratory throughput. There is also growing interest in rapid and accessible diagnostic solutions that can support testing beyond traditional centralized laboratories.

Sandwich, competitive, and indirect ELISA kits form the main product categories, while clinical diagnostics, research laboratories, and blood donation screening drive application demand. Clinical diagnostics remains the largest segment because of the ongoing need for reliable HCV detection.

Hospitals and diagnostic laboratories are major end users, while blood banks increasingly integrate antibody testing to support the safety of donated blood. North America maintains the leading regional position, followed by Europe, with Asia-Pacific offering additional growth potential.

The market has further potential through AI-driven diagnostic tools, point-of-care technologies, and expanded screening initiatives. Partnerships with healthcare providers and organizations could help improve awareness and extend HCV testing to regions where laboratory access remains limited.